Investment Thesis
Lite Strategy operates as a fundamentally broken business with near-zero revenue ($214K) while incurring $55M+ in annual operating losses and burning $8M in cash flow annually. With only 11 months of cash runway at current burn rates and no clear path to profitability, the company faces existential risk unless it achieves significant operational restructuring or capital infusion.
Strengths
- Zero long-term debt provides financial flexibility and eliminates refinancing risk
- Strong liquidity position with 11.5x current ratio and $7.5M cash reserves
- Low liability burden ($952K) relative to asset base of $57.8M
Risks
- Revenue collapse to $214K (-100% YoY) indicates complete business failure or pre-revenue pharmaceutical shell with no commercialization
- Operating burn of $8M annually with only ~11 months of cash runway before depletion at current burn rates
- Negative operating cash flow and massive operating losses (-$55.2M) with no demonstrated path to profitability or positive unit economics
- As pharmaceutical company with near-zero revenue, R&D spending likely unmatched by any viable product pipeline
Key Metrics to Watch
- Quarterly revenue and gross margin trends - critical indicator of any commercial traction
- Monthly operating cash burn rate - determines time to insolvency
- Cash balance and runway remaining - direct measure of survival timeline
Financial Metrics
Revenue
214.0K
Net Income
-58.1M
EPS (Diluted)
$-1.68
Free Cash Flow
-8.0M
Total Assets
57.8M
Cash
7.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-25,801.9%
Net Margin
-27,164.5%
ROE
-102.3%
ROA
-100.6%
FCF Margin
-3,718.2%
Balance Sheet & Liquidity
Current Ratio
11.53x
Quick Ratio
11.53x
Debt/Equity
0.00x
Debt/Assets
1.6%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T08:45:32.532888 |
Data as of: 2026-03-31 |
Powered by Claude AI